Sanofi no longer plays the letter of Made in France. After the stormy assignment of 50 % of the shares ofOpellaMother House in Doliprane, the French pharmaceutical laboratory will relieve a new site in Maisons-Alfort. According to the specialized average actulabo, it should fall into the German warning Adragos Pharma.
According to the French pharmaceutical giant unions, the fate of the factory will be discussed on Tuesday during a meeting between the administration and the personnel representatives. The announcement of this site transfer project, which manufactures an anticoagulant and uses 600 people, made the unions at the beginning of the week.
Sanofi says that “the closure of the Maisons-Alfort site is completely excluded and that everything is done to build a sustainable project, which will maintain the activity and use of this establishment.” “In this perspective, we summon an extraordinary meeting of the bodies on July 1,” the group wrote.
In a press release published on Friday, President (LR) of the Ile-De-France region, Valérie Pécresse, and the president of the Departmental Council, Mayor of Maisons-Alforo, the deputy of the District, Olivier captain, evoke a “brutal announcement”, “which is carried out in a progressive abandonment by Sanofi of its departmental locations.”
They claim to meet with the supposed buyer as quickly as possible, to ensure the future of the site. Almost 600 employees work there. Sanofi explains that the medication produced on the site, an anticoagulant called Lovenox, is now competed for more competitive extractor productions. But he adds that the site “has a real industrial value.” “The closure of the Maisons-Alfort site is completely excluded,” said Sanofi.
Immunology strategy
Above all, the industrial tool on the site, deployed since 1948, is not part of the strategic turning point taken by Sanofi.
However, the group retains another factory that manufactures this product, in Hungary, with lower production costs. In France, they reorganize their activities: it recently closed a factory in Gentilly, but reinforced its site in Versy-Sur-Seine. In this last site, it will double the production of monoclonal antibodies, a sign of a strategic turn initiated towards immunology.
Sanofi seeks to relieve that non -perfitable activities are particularly in current medications, to go to sectors with greater added value, oncology to immunology. The group wants to distance itself from its main growth engine at this time, the Dupixent, used to treat dermatitis. For example, he opted 9 billion in June for the Biotechnology Plan.
Hearing in the National Assembly as part of a parliamentary investigation on deindustrialization in France, on June 13, the president of Sanofi, Audrey Duval, had warned possible transfers.
Sanofi emphasizes that the sites sold for ten years have never closed after sale.
Source: BFM TV
